Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC9A1 | P19634 | 7/20 | 0.73 |
| ▸ | SLC9A2 | Q9UBY0 | 4/20 | 0.65 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.64 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.64 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.64 |
| ▸ | MALT1 | Q9UDY8 | 13/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6321368 | 0.99 | SLC9A1 (0.71) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL3716453 | 0.94 | SLC9A1 (0.70) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL6319943 | 0.93 | SLC9A1 (0.69) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL6312185 | 0.91 | SLC9A1 (0.74) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL6400008 | 0.86 | SLC9A1 (0.70) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL6313076 | 0.86 | SLC9A1 (0.70) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6312521 | 0.86 | SLC9A1 (0.54) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL6212911 | 0.85 | SLC9A1 (0.52) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| Hydrochloric Acid SCHEMBL6314142 | 0.83 | SLC9A1 (0.98) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 | |
| SCHEMBL4458530 | 0.82 | MALT1 (0.54) | SLC9A1SLC9A2OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | claimed |
| EP-1056729-B1 | N-[(SUBSTITUTED FIVE-MEMBERED DI- OR TRIAZA DIUNSATURATED RING)CARBONYL]GUANIDINE DERIVATIVES FOR THE TREATMENT OF ISCHEMIA | PFIZER PROD INC (US) | 2004-12-29 | — | — | EP | claimed |
| US-6602875-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC | 2003-08-05 | — | — | US | claimed |
| US-20030055021-A1 | Compounds for the treatment of ischemia | PFIZER, INC. | 2003-03-20 | — | — | US | claimed |
| CN-1374967-A | Compounds for the treatment of ischemia | PFIZER PROD INC (US) | 2002-10-16 | — | — | CN | claimed |
| CN-1370531-A | Combined therapy | PFIZER PRODUCT CO (US) | 2002-09-25 | — | — | CN | claimed |
| CN-1289326-A | N-[(substituted five-membered di-or thiaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER PROD INC (US) | 2001-03-28 | — | — | CN | claimed |
| US-7572910-B2 | Pyridazinone aldose reductase inhibitors | PFIZER, INC. (US) | 2009-08-11 | — | — | US | disclosed |
| US-20050171049-A1 | Compounds for the treatment of ischemia | DENINNO MICHAEL P (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050113381-A1 | Pyridazinone aldose reductase inhibitors | MYLARI BANAVARA L (US) | 2005-05-26 | — | — | US | disclosed |
| US-6894047-B2 | Triazine compounds useful as sorbitol dehydrogenase inhibitors | PFIZER INC. (US) | 2005-05-17 | — | — | US | disclosed |
| US-6869943-B2 | Sorbitol dehydrogenase inhibitors | PFIZER INC (US) | 2005-03-22 | — | — | US | disclosed |
| US-6803457-B1 | ADENOSINE RECEPTORS; FOR REDUCTION OF TISSUE DAMAGE RESULTING FROM HYPOXIA/CARDIOVASCULAR DISORDERS IN MAMMALS/HUMANS | PFIZER, INC. | 2004-10-12 | — | — | US | disclosed |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | CHU-MOYER MARGARET Y (US) | 2004-04-22 | — | — | US | disclosed |
| US-20030212104-A1 | Treatment of diabetes and diabetic complications with NHE-1 inhibitors | PFIZER INC. | 2003-11-13 | — | — | US | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| CN-1374967-A | Compounds for the treatment of ischemia | PFIZER PROD INC (US) | 2002-10-16 | — | — | CN | disclosed |
| CN-1370531-A | Combined therapy | PFIZER PRODUCT CO (US) | 2002-09-25 | — | — | CN | disclosed |
| US-20020099075-A1 | COMBINATION THERAPY | TRACEY WAYNE R (US) | 2002-07-25 | — | — | US | disclosed |
| CN-1289326-A | N-[(substituted five-membered di-or thiaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER PROD INC (US) | 2001-03-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171049-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, TBXA2R | SLC9A1 1320/4885SLC9A2 1706/4885OPRM1 379/4885 |
| US-20030212104-A1 | Treatment of diabetes and diabetic complications with NHE-1 inhibitors | NHERF1, SLC5A1, SLC5A2 | SLC9A1 6/4885SLC9A2 7/4885OPRM1 4128/4885 |
| US-20050113381-A1 | Pyridazinone aldose reductase inhibitors | SLC5A1, ALDOA, AKR1B1 | SLC9A1 90/4885SLC9A2 235/4885OPRM1 3152/4885 |
| US-20030055021-A1 | Compounds for the treatment of ischemia | TNNI3, ADRB3, FABP3 | SLC9A1 1826/4885SLC9A2 2444/4885OPRM1 223/4885 |
| US-20040077671-A1 | Sorbitol dehydrogenase inhibitors | SLC5A1, SORD, SLC5A2 | SLC9A1 14/4885SLC9A2 23/4885OPRM1 3431/4885 |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | SLC9A1 5/4885SLC9A2 12/4885OPRM1 2426/4885 |
| US-20020099075-A1 | COMBINATION THERAPY | TFPI, SLC9A1, TFPI2 | SLC9A1 2/4885SLC9A2 13/4885OPRM1 1964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.